Back to search results

Study of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide for Relapsed B-cell Lymphoma

This study is looking into a combination of four medicines: mosunetuzumab, polatuzumab vedotin, tafasitamab, and lenalidomide. These medicines are given to people with B-cell non-Hodgkin lymphoma (NHL) that has come back (relapsed) or is not responding to other treatments. The main goal is to see how safe this combination is and how well it shrinks the lymphoma. Researchers will also look at how many people have their lymphoma completely disappear, how long the response lasts, and how long people live without the lymphoma getting worse. You may be able to join if you have relapsed CD20+ Follicular Lymphoma or relapsed CD20+ diffuse large B-cell lymphoma. The study plans to enroll 36 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive specific treatments. It plans to enroll 36 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The best overall response rate will be measured through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05615636

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Recruiting
PHASE2Ages 18+InterventionalTreatment
M.D. Anderson Cancer Center
~36 participants
Updated 2026-05-20 on ClinicalTrials.gov
What's tested:MosunetuzumabPolatuzumab vedotinTafasitamabLenalidomide

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The best overall response rate (ORR).
Measured over through study completion; an average of 1 year.

Conditions

Hodgkin Lymphoma
B-Cell Lymphoma
Relapsed B-cell NHL

Explore related trials

B-Cell Non-Hodgkin LymphomaDiffuse Large B-Cell LymphomaFollicular LymphomaMS4A1 Gene

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Jason Westin, MD, MS, FACP · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Jason Westin, MD, MS, FACP
[email protected]
713-792-3750
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

A diagnosis of relapsed CD20+ Follicular Lymphoma grade 1-3a
A diagnosis of relapsed CD20+ diffuse large B-cell lymphoma
Hemoglobin ≥ 9.0 g/dL
Absolute neutrophil count ≥ 1.0 x 109/L
Platelet count ≥ 75 x 109/L 6. Serum bilirubin \<1.5x ULN except in patients with Gilbert fs syndrome as defined by \> 80% unconjugated bilirubin who must have a serum bilirubin of \<4x ULN; AST (SGOT) and ALT (SGPT) ≤ 3x ULN or \< 5x ULN if hepatic metastases are present 7. Renal function assessed by calculated creatinine clearance:

What this trial measures

  • The best overall response rate (ORR).through study completion; an average of 1 year.